Organic Active Ingredients TRIZ Cases

Defined BCL-2 inhibitor structures modulate cell proliferation to address inadequate inhibition of anti-apoptotic proteins in cancer treatment.

A combinatorial targeted therapy method assigns drugs to local or systemic delivery based on genomic profiles.

Golexanolone treats fatigue and cognitive impairment in non-cirrhotic chronic liver disease patients with elevated serum allopregnanolone levels.

Dual-action piperazine derivatives inhibit serotonin reuptake and block NK1 receptors to reduce emetogenic effects.

PDGFRb modulators inhibit tumor metastasis by targeting platelet-derived growth factor receptor beta activity in mutant p53-expressing cancers.

Targets ADAR1 and ISG15 to overcome checkpoint blockade resistance by enhancing interferon signaling in tumor immunity.

Specific molecular structures target FABP4 to improve glucose consumption in adipocytes, addressing incomplete modulation of metabolic pathways.

An injectable polymer solution gels in situ to eliminate surgical implantation risks while ensuring sustained drug release.

Isonicotinic acid forms a hydrated complex with gallated epicatechins, achieving >97% purity from green tea extract.

Probiotic arginolytic oral compositions enhance ammonia production via the arginine deiminase system to inhibit caries-associated bacteria.

Combining IAP inhibitors with oncolytic viruses enhances tumor cell killing through synergistic Caspase activation.

A quaternized tubulysin conjugate uses a cleavable linker to release the active drug at the target site.

Trans-(E) doxepin isomer mixtures selectively bind histamine H1 receptors, reducing addiction risk and adverse effects associated with traditional hypnotics.

A temperature-responsive polymer increases ocular tension by aggregating at body heat to block aqueous humor drainage.

Ergosterol facilitates vitamin D2 synthesis via UV photoisomerization, addressing vegan precursor bans and excessive sunlight risks.

A fusion protein combines an antigen-binding domain with a stress protein to target cancer cells and activate dendritic cells.

Forodesine combined with Bendamustine overcomes drug resistance in hematologic cancers by targeting the ATM/p53 pathway.

6,7-Dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives act as negative allosteric modulators of the mGluR2 receptor.

A CLDN18.2 antibody-drug conjugate uses a self-immolative linker to release cytotoxic payloads inside target cells.

A chemical synthesis method constructs Pseudomonas aeruginosa O-antigen trisaccharides using specific saccharide building blocks and a mixed solvent system.

Form A sodium caprate enables direct tablet compression, reducing stickiness and boosting tensile strength.

Segmented nucleic acid structures bypass adaptive immunity deficits by directly stimulating innate pathways for broad viral protection.

Substituted cinnoline derivatives inhibit Bruton's tyrosine kinase to treat lymphoma and autoimmune diseases.

A dutasteride solid dispersion coprecipitate with a water-soluble polymeric carrier improves dissolution rate without harmful stabilizers.

MYK-3 antibody-drug conjugate targets EGFR mutations in non-small cell lung cancer, overcoming AZD9291 drug resistance.

Peptide-oleic acid complex disrupts tumor membranes to increase chemotherapy uptake, reducing healthy cell toxicity.

Substituted aromatic compounds inhibit collagen secretion and deposition, reducing fibrosis progression in lungs, liver, skin, and heart.

Heterocyclic ATR kinase inhibitors target genomic instability in cancer cells, resolving treatment gaps for DNA repair deficient tumors.

A natural herbal powder formulation enhances cellular and humoral immune functions through rapid cold water dissolution.

Selective 5-HT2A inverse agonism treats Parkinson's psychosis without D2 blockade, eliminating extrapyramidal side effects and weight gain.

HPTP-β inhibitors regulate angiogenesis by blocking phosphatase activity, improving tissue blood flow and treating vascular leakage syndrome.

Methylnaltrexone ion pairs with sodium lauryl sulfate to boost lipophilicity, resolving poor oral bioavailability and inconsistent laxation efficacy.

New antifibrotic compounds inhibit type 1 collagen synthesis to treat fibrosis while reducing toxicity compared to existing treatments.

Novel pyrazolo[3,4-b]pyridine compounds act as antagonists against Toll-like receptors 7 and 8 to inhibit inflammatory signaling pathways.

Targeted deuterium substitution increases carbonyl group T1 relaxivity, resolving the trade-off between membrane permeability and MRI compatibility.

[1,2,4]Triazolo[1,5-a]pyridinyl substituted indole compounds reduce cytokine production and B cell activation to mitigate inflammatory responses.

Bicyclic heteroaryl benzamide compounds inhibit Trk kinases to treat pain, cancer, and inflammation while reducing side effects.

Macrogol 15 hydroxystearate solubilizes prostamide drugs to overcome rapid precorneal elimination and enhance ocular bioavailability.

Optimized aripiprazole prodrug suspensions reduce the 14-day oral lead-in period required by existing extended-release injectables.

Alkyl-substituted L-glutamate derivatives modulate TH1, TH2, and TH17 responses to reduce adverse effects from conventional corticosteroid treatments.

Covalent kartogenin-chitosan conjugates extend joint retention time and improve chondrogenic differentiation efficiency.

Composite filler matrix controls nicotine release duration while maintaining comfortable texture and resisting humidity changes.